Currently, the presence of the BLB impedes the systemic drug administration of drugs to the inner ear, while the discovery of LRP1 and its ligand IETP2 may provide a new avenue for noninvasive and systemic administration that is feasible for patients with inner ear disorders. This evidence concerns the gene LRP1 and inner ear disorder.